BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 30188361)

  • 1. Diagnostic and Predictive Immunohistochemistry for Non-Small Cell Lung Carcinomas.
    Hung YP; Sholl LM
    Adv Anat Pathol; 2018 Nov; 25(6):374-386. PubMed ID: 30188361
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Automated chromogenic multiplexed immunohistochemistry assay for diagnosis and predictive biomarker testing in non-small cell lung cancer.
    Ilie M; Beaulande M; Hamila M; Erb G; Hofman V; Hofman P
    Lung Cancer; 2018 Oct; 124():90-94. PubMed ID: 30268486
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SMARCA4/BRG1-Deficient Non-Small Cell Lung Carcinomas: A Case Series and Review of the Literature.
    Nambirajan A; Singh V; Bhardwaj N; Mittal S; Kumar S; Jain D
    Arch Pathol Lab Med; 2021 Jan; 145(1):90-98. PubMed ID: 33367658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chromogenic immunohistochemical quadruplex provides accurate diagnostic differentiation of non-small cell lung cancer.
    Roberts EA; Morrison LE; Behman LJ; Draganova-Tacheva R; O'Neill R; Solomides CC
    Ann Diagn Pathol; 2020 Apr; 45():151454. PubMed ID: 31923744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expanding the Immunophenotype Spectrum of SMARCA4-Deficient Non-Small Cell Lung Carcinomas: A Case Series with Neuroendocrine Markers Expression.
    Mao R; Liu M; Shu X; Li W; Yan W; Li X
    Int J Surg Pathol; 2022 May; 30(3):251-259. PubMed ID: 34633874
    [No Abstract]   [Full Text] [Related]  

  • 6. Does Immunohistochemistry Represent a Robust Alternative Technique in Determining Drugable Predictive Gene Alterations in Non-Small Cell Lung Cancer?
    Rossi G; Ragazzi M; Tamagnini I; Mengoli MC; Vincenzi G; Barbieri F; Piccioli S; Bisagni A; Vavala T; Righi L; Novello S; Gelsomino F; Tiseo M
    Curr Drug Targets; 2017; 18(1):13-26. PubMed ID: 25901525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Significance of the PD-L1 Expression in Non-Small-Cell Lung Cancer: Trenchant Double Swords as Predictive and Prognostic Markers.
    Takada K; Toyokawa G; Shoji F; Okamoto T; Maehara Y
    Clin Lung Cancer; 2018 Mar; 19(2):120-129. PubMed ID: 29153898
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SMARCA4/BRG1 Is a Novel Prognostic Biomarker Predictive of Cisplatin-Based Chemotherapy Outcomes in Resected Non-Small Cell Lung Cancer.
    Bell EH; Chakraborty AR; Mo X; Liu Z; Shilo K; Kirste S; Stegmaier P; McNulty M; Karachaliou N; Rosell R; Bepler G; Carbone DP; Chakravarti A
    Clin Cancer Res; 2016 May; 22(10):2396-404. PubMed ID: 26671993
    [TBL] [Abstract][Full Text] [Related]  

  • 9. c-MET Overexpression as a Poor Predictor of MET Amplifications or Exon 14 Mutations in Lung Sarcomatoid Carcinomas.
    Mignard X; Ruppert AM; Antoine M; Vasseur J; Girard N; Mazières J; Moro-Sibilot D; Fallet V; Rabbe N; Thivolet-Bejui F; Rouquette I; Lantuejoul S; Cortot A; Saffroy R; Cadranel J; Lemoine A; Wislez M
    J Thorac Oncol; 2018 Dec; 13(12):1962-1967. PubMed ID: 30149144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Parallel screening for ALK, MET and ROS1 alterations in non-small cell lung cancer with implications for daily routine testing.
    Jurmeister P; Lenze D; Berg E; Mende S; Schäper F; Kellner U; Herbst H; Sers C; Budczies J; Dietel M; Hummel M; von Laffert M
    Lung Cancer; 2015 Feb; 87(2):122-9. PubMed ID: 25534130
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches.
    Shea M; Costa DB; Rangachari D
    Ther Adv Respir Dis; 2016 Apr; 10(2):113-29. PubMed ID: 26620497
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytology of SMARCA4-Deficient Thoracic Neoplasms: Comparative Analysis of SMARCA4-Deficient Non-Small Cell Lung Carcinomas and SMARCA4-Deficient Thoracic Sarcomas.
    Nambirajan A; Dutta R; Malik PS; Bubendorf L; Jain D
    Acta Cytol; 2021; 65(1):67-74. PubMed ID: 32854100
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Diagnosis, prognosis, and prediction of non-small cell lung cancer. Importance of morphology, immunohistochemistry and molecular pathology].
    Warth A
    Pathologe; 2015 Nov; 36 Suppl 2():194-200. PubMed ID: 26391251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SMARCA4-deficient pulmonary adenocarcinoma: clinicopathological, immunohistochemical, and molecular characteristics of a novel aggressive neoplasm with a consistent TTF1
    Agaimy A; Fuchs F; Moskalev EA; Sirbu H; Hartmann A; Haller F
    Virchows Arch; 2017 Nov; 471(5):599-609. PubMed ID: 28555282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): Moving from targeted therapy to immunotherapy.
    Osmani L; Askin F; Gabrielson E; Li QK
    Semin Cancer Biol; 2018 Oct; 52(Pt 1):103-109. PubMed ID: 29183778
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subtyping of undifferentiated non-small cell carcinomas in bronchial biopsy specimens.
    Loo PS; Thomas SC; Nicolson MC; Fyfe MN; Kerr KM
    J Thorac Oncol; 2010 Apr; 5(4):442-7. PubMed ID: 20195168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical characteristics and prognostic analysis of SMARCA4-deficient non-small cell lung cancer.
    Liang X; Gao X; Wang F; Li S; Zhou Y; Guo P; Meng Y; Lu T
    Cancer Med; 2023 Jul; 12(13):14171-14182. PubMed ID: 37184108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-small cell lung cancer with loss of expression of the SWI/SNF complex is associated with aggressive clinicopathological features, PD-L1-positive status, and high tumor mutation burden.
    Naito T; Udagawa H; Umemura S; Sakai T; Zenke Y; Kirita K; Matsumoto S; Yoh K; Niho S; Tsuboi M; Ishii G; Goto K
    Lung Cancer; 2019 Dec; 138():35-42. PubMed ID: 31630044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A genomic and clinicopathological study of non-small-cell lung cancers with discordant ROS1 gene status by fluorescence in-situ hybridisation and immunohistochemical analysis.
    Zhao J; Chen X; Zheng J; Kong M; Wang B; Ding W
    Histopathology; 2018 Jul; 73(1):19-28. PubMed ID: 29464758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PD-L1 expression in non-small cell lung carcinoma: Comparison among cytology, small biopsy, and surgical resection specimens.
    Heymann JJ; Bulman WA; Swinarski D; Pagan CA; Crapanzano JP; Haghighi M; Fazlollahi L; Stoopler MB; Sonett JR; Sacher AG; Shu CA; Rizvi NA; Saqi A
    Cancer Cytopathol; 2017 Dec; 125(12):896-907. PubMed ID: 29024471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.